Shanton, Present

Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

Published on 08/07/2025 at 18:08 | prnewswire.co.uk

Shanton Pharma New Jersey Singapore

View original content:https://www.prnewswire.co.uk/news-releases/shanton-to-present-topline-data-from-phase-2b-study-with-sap-001-in-refractory-gout-patients-at-eular-2025-congress-302457828.html

en | boerse | 67934753 |